logo

Vistagen Therapeutics Inc (VTGN)



Trade VTGN now with
  Date
  Headline
2/13/2019 8:40:49 AM VistaGen Therapeutics Receives Notice Of Allowance For U.S. Patent For Treatment Of Depression With PH10
10/25/2018 9:20:50 AM VistaGen Therapeutics Acquires Worldwide Rights To Develop And Commercialize PH10
10/3/2018 8:34:43 AM VistaGen Receives FDA Fast Track Designation For Development Of AV-101 As Non-Opioid Treatment For Neuropathic Pain
9/13/2018 8:36:26 AM VistaGen Therapeutics Buys Worldwide License Of Phase 3-Ready CNS Drug Candidate From Pherin
8/14/2018 4:50:49 PM VistaGen Therapeutics Q1 Loss/share $0.20 Vs. Loss $0.28 Year Ago
8/13/2018 8:35:41 AM VistaGen, Baylor College Of Medicine To Test VistaGen’s AV-101 For Potential Anti-Suicidal Effects In Veterans
6/26/2018 5:23:49 PM VistaGen Therapeutics FY18 Loss/share $1.12 Vs. Loss $1.54 Year Ago
6/11/2018 8:41:37 AM VistaGen Therapeutics Receives Notice Of Allowance For Japanese Patent For Use Of Stem Cells
5/23/2018 8:37:26 AM VistaGen Therapeutics Receives Notice Of Allowance Of U.S. Patent For Treatment Of Osteoarthritis And Joint Injuries
5/2/2018 8:35:50 AM VistaGen Receives Notice Of Allowance For Japanese Patent Regarding Methods Of Production For AV-101
4/10/2018 8:32:50 AM VistaGen Receives European Patent Regarding Methods Of Production For AV-101
1/3/2018 8:33:36 AM VistaGen: FDA Grants Fast Track Designation To AV-101 For Treatment Of Major Depressive Disorder